Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

JollyAcorn2021 Apr. 28 at 7:24 PM

$GALT L. F. G.

0 · Reply

D_Coral Apr. 28 at 7:10 PM

$GALT $XBI Advancing Real-Time Clinical Trials The U.S. Food and Drug Administration will announce two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT). WHO: • Commissioner of Food and Drugs Marty Makary, MD, MPH • FDA Chief AI Officer Jeremy Walsh • FDA Deputy Chief Medical Officer Mallika Mundkur https://www.youtube.com/live/hPT6X4SKOjw?si=Bqzw0BhtMhZd6lng

0 · Reply

JollyAcorn2021 Apr. 28 at 7:03 PM

$GALT I had a horror thought that the type c meeting happens and they announce the FDA is pleased with the elastography readings and the company announces revised endpoints confirmed to be by Fibroscan in place of endoscopy... and also to request an additional type c meeting to fully discuss the bio marker data. 😉😆🤫

3 · Reply

ThomasLD Apr. 28 at 6:08 PM

$GALT This is very interesting if this drug is fully approved. No way we will get $292.8 a share but will see how Richard can negotiate! 1.7m estimation was for cirrhosis & csph without varices in 2024 in the US. Now, 3.3m is for cirrhosis & csph with and without varices. 3.3M x30% ~ 990,000 x $35,000 ~ $34.6B / 0.118135821 ~ $292.8+ a share.

1 · Reply

JollyAcorn2021 Apr. 28 at 5:48 PM

$GALT As of 1:45 PM eastern time, nly 80,020 shares traded in the first 4.25 hours of trading!? That is a pace that will result in a 122,352 share day if nothing changes. That is LOW volume even for GALT. Wonder why the pause y the shorts? No churn today? No dark pool?

1 · Reply

Indibviduate1 Apr. 28 at 2:47 PM

$GALT yes. The clinical trial results show they also stop existing varices from getting larger so the market should be for patients with cirrhosis and csph both with and without varices. IMHO

0 · Reply

Langer09 Apr. 28 at 2:43 PM

$GALT This is where they are getting the 1.7M # from....

0 · Reply

Indibviduate1 Apr. 28 at 2:38 PM

$GALT number of patients with cirrhosis and portal hyoertension is no longer 1.7 million when galectin therapeutics had an outside assessor estimate revenue This is their latest chart. From their website. The patient numbers have doubled.

0 · Reply

bernoneill Apr. 28 at 2:27 PM

$GALT See page 6 https://investor.galectintherapeutics.com/static-files/1720e267-d0b6-4cad-9764-712855246fb6

1 · Reply

dmacw Apr. 28 at 2:23 PM

$GALT Down 31 cents since the Zacks upgrade to buy! Make sense?

1 · Reply

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm

Mar 10, 2026, 12:00 PM EDT - 7 weeks ago

Galectin Therapeutics Transcript: KOL event

Jan 7, 2026, 10:40 AM EST - 3 months ago

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Dec 29, 2025, 9:54 PM EST - 4 months ago

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

Dec 3, 2025, 11:00 AM EST - 5 months ago

Galectin Therapeutics Transcript: AGM 2025

Nov 14, 2025, 8:00 AM EST - 5 months ago

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Galectin Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference

Sep 8, 2025, 1:00 PM EDT - 8 months ago

Galectin Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jun 16, 2025, 12:00 PM EDT - 11 months ago

Galectin Therapeutics Transcript: Study Result

May 12, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 1 year ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 1 year ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Oct 7, 2024, 10:00 AM EDT - 1 year ago

Galectin Therapeutics Transcript: 9th Annual MASH Investor Conference

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 2 years ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 4 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Dec 3, 2021, 11:00 AM EST - 4 years ago

Galectin Therapeutics Transcript: AGM 2021

JollyAcorn2021 Apr. 28 at 7:24 PM

$GALT L. F. G.

0 · Reply

D_Coral Apr. 28 at 7:10 PM

0 · Reply

JollyAcorn2021 Apr. 28 at 7:03 PM

3 · Reply

ThomasLD Apr. 28 at 6:08 PM

1 · Reply

JollyAcorn2021 Apr. 28 at 5:48 PM

1 · Reply

Indibviduate1 Apr. 28 at 2:47 PM

$GALT yes. The clinical trial results show they also stop existing varices from getting larger so the market should be for patients with cirrhosis and csph both with and without varices. IMHO

0 · Reply

Langer09 Apr. 28 at 2:43 PM

$GALT This is where they are getting the 1.7M # from....

0 · Reply

Indibviduate1 Apr. 28 at 2:38 PM

0 · Reply

bernoneill Apr. 28 at 2:27 PM

$GALT See page 6 https://investor.galectintherapeutics.com/static-files/1720e267-d0b6-4cad-9764-712855246fb6

1 · Reply

dmacw Apr. 28 at 2:23 PM

$GALT Down 31 cents since the Zacks upgrade to buy! Make sense?

1 · Reply

Nelly0414 Apr. 28 at 1:58 PM

$GALT 1.7 million people maybe??????

0 · Reply

Ah9020 Apr. 28 at 1:28 PM

$GALT this was just posted on Webull. Peak sales 1.7 million???? What?

1 · Reply

ThomasLD Apr. 28 at 1:25 PM

$GALT Think what you want. Below from GALT CMO. Belapectin is for “a population for whom there are currently no approved treatment options”. “These findings have been well received by the scientific community and were recently discussed by leading hepatology experts during our March 10, 2026 virtual KOL event, where the data were reviewed in the context of disease progression and portal hypertension category risk in MASH cirrhosis. Taken together, these results further strengthen the biological rationale for galectin-3 inhibition and support continued evaluation of belapectin as a potential therapy for patients with MASH cirrhosis, a population for whom there are currently no approved treatment options”.

0 · Reply

Scarlivertriumphant Apr. 28 at 12:40 PM

$GALT The FGF21 drugs have been bought out by BP. They are targeting an earlier stage of MASH- F2 F3. GALT is targeting cACLD with CSPH. To review the nomenclature: cACLD= compensated advanced chronic liver disease. CSPH= clinically significant portal hypertension. cACLD refers to people whose fibrosis/cirrhosis is very advanced but are asymptomatic, and who are at risk for developing CSPH. The confusion that is arising occurs when companies say F4, or F4c. This is an earlier stage of the disease process. I believe these companies are confusing the investing public. (? intentional) FGF21 drugs have serious potential risks in cACLD with CSPH patients. Thise risks are of muscle loss (sarcopenia) and bone loss (osteoporosis). Just like you can't infer drug effectiveness in cACLD from their actions in F2F3 (that was made very clear at Baveno VIII), you cannot infer drug safety profiles in cACLD with CSPH from their safety profiles in earlier MASH stages.

1 · Reply

Indibviduate1 Apr. 28 at 12:02 PM

$GALT fgf21. Just one of many and it’s for f2-3. Different stage of the disease than csph with cirrhosis. No competition and many of these already owned by bp

1 · Reply

SNOWBALLDB321 Apr. 28 at 11:18 AM

$GALT Can anyonne comment on the significance of Efimosfermin getting an fda breakthrough status for potential fibrosis reversal in mash and how it affects GALT.

3 · Reply

DragonAlgo Apr. 28 at 9:41 AM

🐉 $GALT CALL — DragonAlgo® Signal Contract: GALT CALL Expiry: 2026-05-15 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.02 Stop: $0.01 TP1: $0.03 TP2: $0.03 TP3: $0.05 🔗 https://dragonalgo.com

0 · Reply

Indibviduate1 Apr. 28 at 8:16 AM

$GALT Survodutide (formerly BI 456906) is an investigational, dual-acting glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is in Phase 3 trials for obesity and Phase 2 for liver fibrosis (MASH/NASH). It showed significant weight loss of nearly 15-19% in trials. Key Details About Survodutide Mechanism of Action: It mimics the actions of both GLP-1 and glucagon, reducing appetite while simultaneously increasing energy expenditure (fat burning). Weight Loss Potential: In Phase 2 trials, participants with obesity (without diabetes) experienced up to 14.9% – 19% weight loss on high doses over 46-48 weeks. Liver Health Focus: It holds US FDA Fast Track Designation for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis). A Phase 2 trial found that 83% of patients with MASH saw significant improvements

1 · Reply

wasserschlag10 Apr. 28 at 6:57 AM

$GALT the warrants May 26 getting into trouble , my bank just advised my to let them know by 19th 9 o’clock if I execute the warrants .

1 · Reply

Indibviduate1 Apr. 28 at 6:57 AM

$GALT Great combination for belapectin. Boehringer had sales of 25 billion last year.

1 · Reply

Indibviduate1 Apr. 28 at 6:07 AM

$GALT It’s a massive unmet need. $29.7 billion revenue per year in the USA. And these patients will take belapectin for the rest of their extended lives. Just for mash cirrhosis with csph Just in the USA which is considered one half of world revenue.

1 · Reply

Indibviduate1 Apr. 28 at 5:33 AM

$GALT

0 · Reply

Market Cap	153.38M
Revenue (ttm)	0.00
Net Income (ttm)	-30.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	103,453
Avg Vol	325,848
Day's Range	N/A - N/A
Shares Out	65.83M
Stochastic %K	27%
Beta	1.03
Analysts	Sell
Price Target	$11.00